10-Q - SKINVISIBLE, INC. (0001085277) (Filer)

Wed, May 14, 6:21 PM (40 days ago)

**Skinvisible, Inc. (SKIN) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $5,000 (flat YoY) - **Gross Profit:** $5,000 (flat YoY) - **Operating Expenses:** $144,852 (up 13% YoY) - **Net Loss:** $281,005 (down 3% YoY) - **Cash Flow from Operations:** -$31,720 (down 158% YoY) - **Cash Flow from Financing:** $34,780 (up 78% YoY) - **Total Assets:** $149,554 (down 5% YoY) - **Total Liabilities:** $9,629,306 (up 3% YoY) - **Stockholders' Deficit:** -$9,479,752 (up 3% YoY) **Key Metrics & Trends:** - **Gross Margin:** 100% (flat YoY) - **Operating Margin:** -2897% (improved 3% YoY) - **Net Margin:** -5620% (improved 3% YoY) - **Cash Burn:** $31,720 (up 158% YoY) - **Working Capital Deficit:** $4,218,598 (up 17% YoY) **Future Operations & Uncertainties:** - **Going Concern:** Significant doubt due to cumulative losses and working capital deficit. - **Funding:** Plans to generate funds through licensing and additional debt/equity financing. - **Market Opportunities:** Exploring new markets and partnerships for Invisicare technology. - **Regulatory:** Progress in Quoin's clinical trials for Netherton Syndrome. - **Internal Controls:** Material weaknesses identified; remediation plans in progress. **Impact on Future Operations:** - **Revenue Growth:** Dependent on successful licensing and partnerships. - **Cost Management:** Increased operating expenses expected; focus on cost-effective solutions. - **Cash Flow:** Negative operating cash flow; reliant on financing activities. - **Risk Factors:** Uncertainties in securing additional financing and regulatory approvals. **Conclusion:** Skinvisible, Inc. faces significant financial challenges, with a substantial working capital deficit and cumulative losses raising substantial doubt about its ability to continue as a going concern. The company's future operations depend heavily on securing additional financing and successful licensing of its core products. Despite these challenges, Skinvisible continues to explore new market opportunities and partnerships for its Invisicare technology.